Risk of hip fracture in Addison's disease: A population-based cohort study

Journal of Internal Medicine

Volumn 270, Issue 2, 2011, Pages 187-195

  Bjornsdottir S ^a   Saaf M ^a   Bensing, S ^a,b   Kampe O ^b   Michaelsson K ^b   Ludvigsson, J F ^a,c  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Addison's disease; Epidemiology; Osteoporotic fractures

Indexed keywords

ADDISON DISEASE; ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FRAGILITY FRACTURE; GROUPS BY AGE; HIP FRACTURE; HUMAN; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; POST HOC ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; REGISTER; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SWEDEN;

ADDISON DISEASE; ADULT; AGE DISTRIBUTION; AGED; COHORT STUDIES; FEMALE; HIP FRACTURES; HUMANS; MALE; MIDDLE AGED; RISK ASSESSMENT; RISK FACTORS; SWEDEN;

EID: 79960215101     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2011.02352.x     Document Type: Article

References (33)

1. Winqvist O, Karlsson FA, Kämpe O. 21-Hydroxylase, a major autoantigen in idiopathic Addison's disease. Lancet 1992; 339: 1559-62.
2. Michels AW, Eisenbarth GS. Autoimmune polyendocrine syndrome type 1 (APS-1) as a model for understanding autoimmune polyendocrine syndrome type 2 (APS-2). J Intern Med 2009; 265: 530-40.
3. Esteban NV, Loughlin T, Yergey AL et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab 1991; 72: 39-45.
4. Reid IR. Preventing glucocorticoid-induced osteoporosis. N Engl J Med 1997; 337: 420-1.
5. Gurnell EM, Hunt PJ, Curran SE et al. Long-term DHEA replacement in primary adrenal insufficiency: a randomized, controlled trial. J Clin Endocrinol Metab 2008; 93: 400-9.
6. Florkowski CM, Holmes SJ, Elliot JR, Donald RA, Espiner EA. Bone mineral density is reduced in female but not male subjects with Addison's disease. N Z Med J 1994; 107: 52-3.
7. Jodar E, Valdepenas MP, Martinez G, Jara A, Hawkins F. Long-term follow-up of bone mineral density in Addison's disease. Clin Endocrinol (Oxf) 2003; 58: 617-20.
8. Arlt W, Rosenthal C, Hahner S, Allolio B. Quality of glucocorticoid replacement in adrenal insufficiency: clinical assessment vs. timed serum cortisol measurements. Clin Endocrinol (Oxf) 2006; 64: 384-9.
9. Løvås K, Gjesdal CG, Christensen M et al. Glucocorticoid replacement therapy and pharmacogenetics in Addison's disease: effects on bone. Eur J Endocrinol 2009; 160: 993-1002.
10. Devogelaer JP, Crabbe J, Nagant de Deuxchaisnes C. Bone mineral density in Addison's disease. Br Med J (Clin Res Ed) 1987; 295: 214.
11. Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med 1994; 120: 207-10.
12. Melton LJ III, Beck TJ, Amin S et al. Contributions of bone density and structure to fracture risk assessment in men and women. Osteoporos Int 2005; 16: 460-7.
13. Melton LJ III, Crowson CS, O'Fallon WM, Wahner HW, Riggs BL. Relative contributions of bone density, bone turnover, and clinical risk factors to long-term fracture prediction. J Bone Miner Res 2003; 18: 312-8.
14. Erichsen MM, Løvås K, Skinningsrud B et al. Clinical, immunological, and genetic features of autoimmune primary adrenal insufficiency: observations from a Norwegian registry. J Clin Endocrinol Metab 2009; 94: 4882-90.
15. Chrischilles EA, Butler CD, Davis CS, Wallace RB. A model of lifetime osteoporosis impact. Arch Intern Med 1991; 151: 2026-32.
16. Chrischilles E, Shireman T, Wallace R. Costs and health effects of osteoporotic fractures. Bone 1994; 15: 377-86.
17. Center JR, Nguyen TV, Schneider D, Sambrook PN, Eisman JA. Mortality after all major types of osteoporotic fracture in men and women: an observational study. Lancet 1999; 353: 878-82.
18. Ludvigsson JF, Otterblad-Olausson P, Pettersson BU, Ekbom A. The Swedish personal identity number: possibilities and pitfalls in healthcare and medical research. Eur J Epidemiol 2009; 24: 659-67.
19. Rodstrom K, Bengtsson C, Milsom I, Lissner L, Sundh V, Bjourkelund C. Evidence for a secular trend in menopausal age: a population study of women in Gothenburg. Menopause 2003; 10: 538-43.
20. Vestergaard P, Mosekilde L. Fractures in patients with hyperthyroidism and hypothyroidism: a nationwide follow-up study in 16, 249 patients. Thyroid 2002; 12: 411-9.
21. Miao J, Brismar K, Nyren O, Ugarph-Morawski A, Ye W. Elevated hip fracture risk in type 1 diabetic patients: a population-based cohort study in Sweden. Diabetes Care 2005; 28: 2850-5.
22. Sher LB, Woitge HW, Adams DJ et al. Transgenic expression of 11beta-hydroxysteroid dehydrogenase type 2 in osteoblasts reveals an anabolic role for endogenous glucocorticoids in bone. Endocrinology 2004; 145: 922-9.
23. Devogelaer JP, Crabbe J, Nagant de Deuxchaisnes C. Bone mineral density in Addison's disease: evidence for an effect of adrenal androgens on bone mass. Br Med J (Clin Res Ed) 1987; 294: 798-800.
24. Arlt W, Callies F, van Vlijmen JC et al. Dehydroepiandrosterone replacement in women with adrenal insufficiency. N Engl J Med 1999; 341: 1013-20.
25. Løvås K, Gebre-Medhin G, Trovik TS et al. Replacement of dehydroepiandrosterone in adrenal failure: no benefit for subjective health status and sexuality in a 9-month, randomized, parallel group clinical trial. J Clin Endocrinol Metab 2003; 88: 1112-8.
26. Miller KK, Biller BM, Hier J, Arena E, Klibanski A. Androgens and bone density in women with hypopituitarism. J Clin Endocrinol Metab 2002; 87: 2770-6.
27. Osmanagaoglu MA, Okumus B, Osmanagaoglu T, Bozkaya H. The relationship between serum dehydroepiandrosterone sulfate concentration and bone mineral density, lipids, and hormone replacement therapy in premenopausal and postmenopausal women. J Womens Health (Larchmt) 2004; 13: 993-9.
28. Hampson G, Bhargava N, Cheung J, Vaja S, Seed PT, Fogelman I. Low circulating estradiol and adrenal androgens concentrations in men on glucocorticoids: a potential contributory factor in steroid-induced osteoporosis. Metabolism 2002; 51: 1458-62.
29. Lombardi F, Franzese A, Iafusco D et al. Bone involvement in clusters of autoimmune diseases: just a complication? Bone 2010; 46: 551-5.
30. Betterle C, Scalici C, Presotto F et al. The natural history of adrenal function in autoimmune patients with adrenal autoantibodies. J Endocrinol 1988; 117: 467-75.
31. Suliman AM, Freaney R, Smith TP, McBrinn Y, Murray B, McKenna TJ. The impact of different glucocorticoid replacement schedules on bone turnover and insulin sensitivity in patients with adrenal insufficiency. Clin Endocrinol (Oxf) 2003; 59: 380-7.
32. Bensing S, Brandt L, Tabaroj F et al. Increased death risk and altered cancer incidence pattern in patients with isolated or combined autoimmune primary adrenocortical insufficiency. Clin Endocrinol (Oxf) 2008; 69: 697-704.
33. Michaëlsson K, Baron JA, Farahmand BY et al. Hormone replacement therapy and risk of hip fracture: population based case-control study. The Swedish Hip Fracture Study Group. BMJ 1998; 316: 1858-63.